Private showcase logo

Private showcase: Accelerating the impact of science

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor

Updated: Mar 04, 2025

Executive Summary

IP Group

MeiraGTx's proprietary 'riboswitch' technology involves the precise control of genetic medicines, initiated by the patient simply taking a pill. This activates the specific genetic medicine to produce the required proteins at the precise time and the precise dosage needed for that particular condition.

Also,

  1. The Mining Code is targeted to be adopted by the International Seabed Authority (ISA) in 2025. Assuming approval from the ISA, TMC intends to commence commercial small-scale commercial production (Project Zero) on the NORI-D area.

  2. Additionally, TMC plans to secure strategic partnerships with key stakeholders, such as battery manufacturers, automotive companies, or other technology firms.

  3. Furthermore, the ongoing publication of key environmental data will continue to highlight TMC’s focus on the environmental impact of any deep-sea mining

Other points,

  • The Mining Code is targeted to be adopted by the International Seabed Authority (ISA) in 2025. Assuming approval from the ISA, TMC intends to commence commercial small-scale commercial production (Project Zero) on the NORI-D area.

  • Additionally, TMC plans to secure strategic partnerships with key stakeholders, such as battery manufacturers, automotive companies, or other technology firms.

Investment Deck

Investment Thesis

Overview of buy and sell case of the business.

Why Invest?

Key pieces of information about the business that you need to know about.

Partnerships

Major pharmaceuticals, J&J and Sanofi, have made strategic investments into MeiraGTx, validating its unique, end-to-end, vertically integrated approach. asd

Next-Gen Technology

MeiraGTx's proprietary 'riboswitch' technology involves the precise control of genetic medicines, initiated by the patient simply taking a pill. This activates the specific genetic medicine to produce the required proteins at the precise time and the precise dosage needed for that particular condition.

Next-Gen Technology

Multiple programs in clinical development all post stage 1 or 2, focused on addressing unmet disease areas. Including but not restricted to X-linked Retinitis Pigmentosa, Inherited Retinal Diseases, Salivary Gland Disorders and Neurodegenerative Diseases

Catalysts

The key events that could drive investment opportunities and shift markets.

Near term

The Mining Code is targeted to be adopted by the International Seabed Authority (ISA) in 2025. Assuming approval from the ISA, TMC intends to commence commercial small-scale commercial production (Project Zero) on the NORI-D area.

Medium term

Additionally, TMC plans to secure strategic partnerships with key stakeholders, such as battery manufacturers, automotive companies, or other technology firms.

Long term

Furthermore, the ongoing publication of key environmental data will continue to highlight TMC’s focus on the environmental impact of any deep-sea mining

Follow the Experts

Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence.

John Walker profile

John Walker

Podcast owner

14 k audience

Expert Insights

youtube
Video Title
Video Link
Justin Fox profile

Justin Fox

Columnist Opinion

20k audience

Expert Insights

youtube
Title
Video link

Investor Materials

Access the most recent investor updates published by the company.

Global warming

Portfolio company Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320

Article

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

External Insights

A curated collection of third-party content relevant to the company and sector to help inform your investment decision.

Global Warming

Istesso receives FDA fast track and orphan drug designation

Article

The page you are looking for doesn't exist or has been moved.

Research

React 19 is coming, what’s new?

React 19 will be another milestone release after the introduction of hooks!

Advanced React Component Design with TypeScript

Let’s explore what sparks might fly when TypeScript and React come together.

How does the React fiber reconciler work?

In this article, I am going to deep dive into the React world and what is the core value proposition of React, what is React reconciler…

Team

Meet the experienced professionals leading our organization

Astro Bestro - undefined

Astro Bestro

Kat Man - undefined

Kat Man

David Smith - undefined

David Smith

Axe man - undefined

Axe man

What the Pro's Are Asking

Here are the questions that institutional investors are asking before making an investment decision.

What's the next 'big thing' within the portfolio?

Two companies that stand out are Hysata and Istesso. Hysata is the world's most efficient hydrogen electrolyser company and has made significant technological process this year. It has received an incredibly high level of commercial interest for such a young company. Istesso discovers and develops drugs for severe chronic diseases such as rheumatoid arthritis. Its current lead compound is in clinical trials and has shown promising signs that it may act as a cure to the underlying condition as well as just treating symptoms.

What are the key challenges IP Group face and how might they be mitigated?

Two companies that stand out are Hysata and Istesso. Hysata is the world's most efficient hydrogen electrolyser company and has made significant technological process this year. It has received an incredibly high level of commercial interest for such a young company. Istesso discovers and develops drugs for severe chronic diseases such as rheumatoid arthritis. Its current lead compound is in clinical trials and has shown promising signs that it may act as a cure to the underlying condition as well as just treating symptoms.

How can IP Group close the discount to NAV?

Two companies that stand out are Hysata and Istesso. Hysata is the world's most efficient hydrogen electrolyser company and has made significant technological process this year. It has received an incredibly high level of commercial interest for such a young company. Istesso discovers and develops drugs for severe chronic diseases such as rheumatoid arthritis. Its current lead compound is in clinical trials and has shown promising signs that it may act as a cure to the underlying condition as well as just treating symptoms.

How can IP Group close the discount to NAV?

Two companies that stand out are Hysata and Istesso. Hysata is the world's most efficient hydrogen electrolyser company and has made significant technological process this year. It has received an incredibly high level of commercial interest for such a young company. Istesso discovers and develops drugs for severe chronic diseases such as rheumatoid arthritis. Its current lead compound is in clinical trials and has shown promising signs that it may act as a cure to the underlying condition as well as just treating symptoms.

How can IP Group close the discount to NAV?

Two companies that stand out are Hysata and Istesso. Hysata is the world's most efficient hydrogen electrolyser company and has made significant technological process this year. It has received an incredibly high level of commercial interest for such a young company. Istesso discovers and develops drugs for severe chronic diseases such as rheumatoid arthritis. Its current lead compound is in clinical trials and has shown promising signs that it may act as a cure to the underlying condition as well as just treating symptoms.